Immucell (ICCC) EBT (2010 - 2026)

Immucell (ICCC) has reported EBT for 17 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 273.3% year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2026 stood at -$596738.0 (down 133.66% YoY), and the FY2025 full-year result was -$1.0 million, up 52.09% from the prior year.
• EBT grew to $1.9 million in Q2 2026 per ICCC's latest filing, from -$2.8 million in the prior quarter.
• Across five years, EBT topped out at $1.9 million in Q2 2026 and bottomed at -$2.8 million in Q4 2025.
• Historically, EBT has averaged -$561795.7 across 5 years, with a median of -$683000.0 in 2022.
• The sharpest annual moves came in 2022 and 2025: EBT tumbled 2314.25% in 2022, then surged 431.91% in 2025.
• Over 5 years, EBT stood at -$1.7 million in 2022, then soared by 31.68% to -$1.1 million in 2023, then soared by 145.73% to $520591.0 in 2024, then sank by 646.65% to -$2.8 million in 2025, then surged by 166.08% to $1.9 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $1.9 million, -$2.8 million, and -$135292.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.